Generating and characterizing immunoreagents to enable studies of
novel emerging viruses is an area where ensembles of synthetic
genes, recombinant antibody pipelines, and modular
antibody-reporter fusion proteins can respond rapidly. Severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues
to spread through the global population causing widespread
morbidity, mortality, and socioeconomic chaos. Using SARS-CoV-2
as our model and starting with a gBlocks encoded nucleocapsid
(N) gene, we purified recombinant protein from
E. coli
, to serve as bait for
selecting semisynthetic nanobodies from our Nomad single-pot
library. Clones were isolated in days and first fused to Gaussia
luciferase to determine EC
50
in the tens of nM range,
and second fused to the ascorbate peroxidase derivative APEX2
for sensitive detection of SARS-CoV-2 infected cells. To
generate inherently fluorescent immunoreagents, we introduce
novel periplasmic sdAb fusions made with mNeonGreen and
mScarlet-I, which were produced at milligram amounts. The
fluorescent fusion proteins enabled concise visualization of
SARS-CoV-2 N in the cytoplasm but not in the nucleus 24 h post
infection, akin to the distribution of SARS-CoV N, thereby
validating these useful imaging tools. SdAb reactivity appeared
specific to SARS-CoV-2 with very much weaker binding to
SARS-CoV, and no noticeable cross-reactivity to a panel of
overexpressed human codon optimized N proteins from other CoV.
High periplasmic expression levels and
in
silico
immortalization of the nanobody constructs
guarantees a cost-effective and reliable source of SARS-CoV-2
immunoreagents. Our proof-of-principle study should be
applicable to known and newly emerging CoV to broaden the tools
available for their analysis and help safeguard human health in
a more proactive than reactive manner.